Format

Send to

Choose Destination
See comment in PubMed Commons below
Lancet. 2016 Jan 16;387(10015):229-38. doi: 10.1016/S0140-6736(15)00471-7. Epub 2015 Oct 19.

5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial.

Author information

1
Department of Radiation Oncology, University Hospital Erlangen, Erlangen, Germany. Electronic address: vratislav.strnad@uk-erlangen.de.
2
Department of Radiation Oncology, University Hospital Erlangen, Erlangen, Germany.
3
Department of Radiation Oncology, University Hospital Leipzig, Leipzig, Germany; Department of Radiation Oncology, University Hospital Rostock, Rostock, Germany.
4
Department of Radiation Oncology, University Hospital AKH Wien, Vienna, Austria.
5
Department of Radiation Oncology, University Hospital Rostock, Rostock, Germany.
6
Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary.
7
Brachytherapy Department, Centrum Onkologii-Instytut im Marii Skłodowskej, Warsaw, Poland; Podkarpacki Hospital Cancer Center Brzozów, Brzozów, Poland.
8
Department of Radiation Oncology, Valencian Institute of Oncology, Valencia, Spain.
9
Department of Radiation Oncology, University Hospital Kiel, Germany.
10
Department of Radiation Oncology, Catalan Institute of Oncology, Barcelona, Spain.
11
Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
12
Department of Radiation Oncology, Hospital Barmherzige Brüder Regensburg, Regensburg, Germany.
13
Department of Radiation Oncology, University Hospital Bern, Inselspital, Bern, Switzerland.
14
Department of Radiation Oncology, University Hospital Würzburg, Würzburg, Germany.
15
Interdisciplinary Brachytherapy Unit, University of Lübeck/UKSH Campus Lübeck, Lübeck, Germany.
16
Department of Radiation Oncology, Clemens Hospital, Münster, Germany.
17
Department of Radiation Oncology, University Hospital Jena, Jena, Germany.
18
Department of Radiation Oncology, University Hospital Erlangen, Erlangen, Germany; Department of Radiation Oncology, University Hospital Rostock, Rostock, Germany.
19
Department of Radiation Oncology, University Hospital Leipzig, Leipzig, Germany.
20
Brachytherapy Department, Centrum Onkologii-Instytut im Marii Skłodowskej, Warsaw, Poland.
21
Department of Radiation Oncology, University Hospital Kiel, Germany; Department of Radiotherapy, Municipal Hospital Cologne, University Witten-Herdecke, Witten, Germany.
22
Department of Medical Informatics, Biometry and Epidemiology, University Erlangen-Nuremberg, Erlangen, Germany.

Abstract

BACKGROUND:

In a phase 3, randomised, non-inferiority trial, accelerated partial breast irradiation (APBI) for patients with stage 0, I, and IIA breast cancer who underwent breast-conserving treatment was compared with whole-breast irradiation. Here, we present 5-year follow-up results.

METHODS:

We did a phase 3, randomised, non-inferiority trial at 16 hospitals and medical centres in seven European countries. 1184 patients with low-risk invasive and ductal carcinoma in situ treated with breast-conserving surgery were centrally randomised to either whole-breast irradiation or APBI using multicatheter brachytherapy. The primary endpoint was local recurrence. Analysis was done according to treatment received. This trial is registered with ClinicalTrials.gov, number NCT00402519.

FINDINGS:

Between April 20, 2004, and July 30, 2009, 551 patients had whole-breast irradiation with tumour-bed boost and 633 patients received APBI using interstitial multicatheter brachytherapy. At 5-year follow-up, nine patients treated with APBI and five patients receiving whole-breast irradiation had a local recurrence; the cumulative incidence of local recurrence was 1.44% (95% CI 0.51-2.38) with APBI and 0.92% (0.12-1.73) with whole-breast irradiation (difference 0.52%, 95% CI -0.72 to 1.75; p=0.42). No grade 4 late side-effects were reported. The 5-year risk of grade 2-3 late side-effects to the skin was 3.2% with APBI versus 5.7% with whole-breast irradiation (p=0.08), and 5-year risk of grade 2-3 subcutaneous tissue late side-effects was 7.6% versus 6.3% (p=0.53). The risk of severe (grade 3) fibrosis at 5 years was 0.2% with whole-breast irradiation and 0% with APBI (p=0.46).

INTERPRETATION:

The difference between treatments was below the relevance margin of 3 percentage points. Therefore, adjuvant APBI using multicatheter brachytherapy after breast-conserving surgery in patients with early breast cancer is not inferior to adjuvant whole-breast irradiation with respect to 5-year local control, disease-free survival, and overall survival.

FUNDING:

German Cancer Aid.

PMID:
26494415
DOI:
10.1016/S0140-6736(15)00471-7
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center